Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MOXIMER-LP
- Development stage
- Unknown
- Lead developer
- Martia Laboratories
- Modality
- Small Molecules
- Administration
- Ophthalmic, Topical
01
Overview
MOXIMER-LP is a preservative-free (BAK-free) ophthalmic combination drug developed by Martia Laboratories for the treatment of bacterial eye infections associated with inflammation. It contains moxifloxacin, a fourth-generation fluoroquinolone antibiotic, and loteprednol etabonate, a corticosteroid. Moxifloxacin exerts its antibacterial effect by inhibiting bacterial DNA gyrase and topoisomerase IV, which are essential for bacterial DNA replication and repair. Loteprednol etabonate acts as a glucocorticoid receptor agonist, blocking the production of prostaglandins and other inflammatory mediators to reduce redness, swelling, and itching. This combination is also used to manage post-operative inflammation following eye surgery.
- Brand names
- MOXIMER-LPMOXIMER-LP Eye Drop BAK Free
- Other names
- MOXIMER-LP Eye Drops
02
Targets
DNA gyraseTopo IV (Bacterial Topoisomerase IV)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on MOXIMER-LP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MOXIMER-LP.